<DOC>
	<DOCNO>NCT01701362</DOCNO>
	<brief_summary>This study design investigate pregabalin effective treating neuropathic ( nerve ) pain result peripheral nerve trauma due traumatic surgical event , example , motor vehicle accident , fall , sport injury , knee hip replacement , hernia repair , thoracotomy , mastectomy , focal/localized burn crush injury .</brief_summary>
	<brief_title>Placebo-controlled Safety Efficacy Study Pregabalin Subjects With Post-traumatic Peripheral Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Subjects must chronic peripheral neuropathic pain present 6 month traumatic surgical event , example , motor vehicle accident , fall , sport injury , knee hip replacement , hernia repair , thoracotomy , mastectomy , focal/localized burn crush injury . Subjects must literate ability ( unaided ) understand use interactive voice response system ( IVRS ) , daily access telephone order complete IVRS assessment day , perform telephone visit complete require assessments/forms . Subjects must sufficient posttraumatic neuropathic pain screen baseline . Subjects neuropathic pain due diabetic peripheral neuropathy ( DPN ) , post herpetic neuralgia ( PHN ) , HIV , trigeminal neuralgia ( TGN ) , carpal tunnel syndrome ( CTS ) central neuropathic pain ( example , due spinal cord injury ) Complex Regional Pain Syndrome ( CRPS , Type I Type II ) . Subjects pain may confound assessment selfevaluation peripheral neuropathic pain . Subjects fail pregabalin treatment due lack efficacy adequate course therapy dose great equal 150 mg/day , previously participate pregabalin clinical trial treat pregabalin time 6 month period prior screen . Subjects epilepsy ; pernicious anemia ; hematological illness ; know HIV infection ; clinically unstable cardiovascular ( include myocardial infarction [ heart attack ] 3 month prior screen ) , hematological , autoimmune , endocrine , renal , hepatic ( include chronic hepatitis B , hepatitis B within 3 month prior screen ) respiratory , gastrointestinal disease ; symptomatic peripheral vascular disease include intermittent claudication ; uncontrolled diabetes mellitus ; untreated hypothyroidism . Subjects diagnosis DSMIV TR Axis I disorder ( include , example , schizophrenia , bipolar disorder ) exception Generalized Anxiety Disorder ( GAD ) major depression clinically stable . Subjects consider risk suicide selfharm base investigator judgment and/or detail risk assessment . Use prohibit medication absence appropriate washout period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>post-traumatic peripheral neuropathic pain</keyword>
</DOC>